By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jazz Pharmaceuticals 

Corporate Headquarters
Fourth Floor, Connaught House

One Burlington Road
Dublin    4  Ireland
Phone: 353-1-634-7800 Fax: 353-1-634-7850


Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in therapeutic areas where we can meaningfully address serious medical needs.

As part of our unwavering commitment to improve patients’ lives, we continue to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing products in our portfolio; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates.

Our Culture

We have a strong patient-focused culture at Jazz Pharmaceuticals that our employees believe in and pursue every day. It is clearly identified through our mission, vision and core values. Each member of our team makes integral contributions and is working toward a common goal to improve patients' lives. Everything we do at Jazz Pharmaceuticals is focused on three things:
• Putting patients first
• Being a great place to work
• Living our core values — integrity, collaboration, passion, pursuit of excellence and innovation

Key Statistics

Ownership: Public

Web Site: Jazz Pharma
Symbol: JAZZ


Company News
Jazz Pharma (JAZZ) Announces Offering Of $500 Million Of 1.50% Exchangeable Senior Notes Due 2024 8/18/2017 6:40:41 AM
Jazz Pharma (JAZZ) Announces Offering Of $500 Million Of Exchangeable Senior Notes Due 2024 8/17/2017 2:40:40 PM
Jazz Pharma (JAZZ) Announces Second Quarter 2017 Financial Results 8/9/2017 12:23:40 PM
Jazz Pharma (JAZZ) Vyxeos Scores FDA Approval in Two AML Types 8/3/2017 8:22:57 AM
Jazz Pharma (JAZZ) And XL-Protein Enter Into A License Agreement On PASylation Technology To Develop Long-Acting Asparaginase Product Candidates 7/27/2017 6:27:59 AM
Jazz Pharma (JAZZ) To Report 2017 Second Quarter Financial Results On August 8, 2017 7/25/2017 10:50:07 AM
Booming Jazz Pharma (JAZZ) Inks Huge Lease in Philadelphia to Accomodate Growth 7/7/2017 6:52:01 AM
Jazz Pharma (JAZZ) Presents JZP-110 Data In Patients With Excessive Sleepiness Associated With Obstructive Sleep Apnea 6/7/2017 7:22:29 AM
Jazz Pharma (JAZZ) Presents Data For The Phase III TONES 2 Study Of JZP-110 In Patients With Excessive Sleepiness Associated With Narcolepsy 6/7/2017 6:29:18 AM
Jazz Pharma (JAZZ) Announces FDA Acceptance Of NDA For VYXEOS (CPX-351), An Investigational Treatment For Acute Myeloid Leukemia, With Priority Review Status 6/1/2017 6:36:20 AM